<DOC>
	<DOCNO>NCT02803892</DOCNO>
	<brief_summary>This study phase 2 , single-center , prospective , randomize , double-blind , placebo-controlled , 3-arm parallel group ( 1:1:1 ) intervention trial determine efficacy 4 week rapamycin treatment 4 week rapamycin treatment plus 3 month vildagliptin treatment versus placebo increase endogenous insulin production correct glycemic lability . It involve 60 patient long stand type 1 diabetes ( T1D ) . Patients receive one month placebo ( Group 1 ) , rapamycin plus placebo ( Group 2 ) , rapamycin plus Vildagliptin ( Group 3 ) . Rapamycin administer initial dose 0.2 mg/kg orally day 0 follow 0.1 mg/kg/die ( target trough level : 8-10 ng/ml ) . Vildagliptin administer dose 50 mg x2/die start day 0 . After 4 week treatment ( period A ) , patient discontinue rapamycin relevant placebo treatment , continue Vildagliptin placebo 8 week monitor period ( period B ) .</brief_summary>
	<brief_title>Monotherapy With Rapamycin Long-standing Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Male female age &gt; 18 year , inclusive Clinical history compatible T1D onset disease &lt; 40 year age , insulin dependence ≥ 5 year time enrolment Cpeptide concentration threshold preserve beta cell function : fasting C peptide &lt; 0.23 ng/ml Detectable fast proinsulin concentration ( &gt; 0.5 pmol/l ) Ability provide write informed consent Mentally stable able comply protocol procedure duration study , include schedule followup visit examination Body mass index ( BMI ) &gt; 30 kg/m2 patient body weight ≤40kg ; Insulin requirement &gt; 1.0 IU/kg/day &lt; 10 U/day ; HbA1c &gt; 11 % ( normal value : 3.56.0 % ) time enrolment estimate glomerular filtration rate &lt; 60 mL/min/1.73m2 calculate use subject 's measure serum creatinine Modification Diet Renal Disease [ MDRD ] study estimation formula ) Presence history macroalbuminuria ( &gt; 300mg/g creatinine ) For female subject : positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation treatment Active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) determine positive skin test clinical presentation , treatment suspect TB Any history malignancy except completely resect squamous basal cell carcinoma skin Lymphopenia ( &lt; 1,000/μL ) , neutropenia ( &lt; 1,500/μL ) , thrombocytopenia ( platelet &lt; 100,000/μL ) . Severe unremitting diarrhea , vomit gastrointestinal disorder potentially interfere ability absorb oral medication Any medical condition interfere safe participation trial ; Any immunosuppressive treatment time enrollment . Allergy active ingredient excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>